B.T. Li

896 total citations
20 papers, 106 citations indexed

About

B.T. Li is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, B.T. Li has authored 20 papers receiving a total of 106 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 12 papers in Pulmonary and Respiratory Medicine and 5 papers in Cancer Research. Recurrent topics in B.T. Li's work include Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). B.T. Li is often cited by papers focused on Lung Cancer Treatments and Mutations (12 papers), HER2/EGFR in Cancer Research (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). B.T. Li collaborates with scholars based in United States, France and Spain. B.T. Li's co-authors include Ramaswamy Govindan, John H. Strickler, Enriqueta Felip, Gerald S. Falchook, Haby Henary, Gataree Ngarmchamnanrith, David Planchard, John C. Krauss, Greg Andrew Durm and David S. Hong and has published in prestigious journals such as Scientific Reports, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

B.T. Li

17 papers receiving 106 citations

Peers

Countries citing papers authored by B.T. Li

Since Specialization

Citations

This map shows the geographic impact of B.T. Li's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by B.T. Li with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites B.T. Li more than expected).

Fields of papers citing papers by B.T. Li

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by B.T. Li. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by B.T. Li. The network helps show where B.T. Li may publish in the future.

Co-authorship network of co-authors of B.T. Li

This figure shows the co-authorship network connecting the top 25 collaborators of B.T. Li. A scholar is included among the top collaborators of B.T. Li based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with B.T. Li. B.T. Li is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Life’s crucial 9 is inversely and linearly associated with female infertility prevalence: a cross-sectional analysis from NHANES 2013–2018 2025 ·Scientific Reports ·B.T. Li, (unknown)	1
2	Serum Homocysteine and Atrial Fibrillation Recurrence after Catheter Ablation: A Meta-Analysis of 11 Cohort Studies Involving 2147 Patients 2024 ·Hormone and Metabolic Research ·B.T. Li, (unknown), (unknown)	0
3	645P Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors 2024 ·Annals of Oncology ·(unknown), Kanika Arora, Vicky Makker, Darren J. Buonocore, (unknown), (unknown), (unknown), (unknown), (unknown), D. Solit, (unknown), (unknown), Mark G. Kris, Pedram Razavi, Joseph R. Drago, Sarat Chandarlapaty, Michael Berger, Alan L. Ho, B.T. Li	1
4	103TiP Sotorasib versus pembrolizumab in combination with platinum doublet chemotherapy as first-line treatment for metastatic or locally advanced, PD-L1 negative, KRAS G12C-mutated NSCLC (CodeBreaK 202) 2024 ·ESMO Open ·Fabrice Barlési, Enriqueta Felip, Sanjay Popat, Benjamin Solomon, Jennifer Moriatis Wolf, B.T. Li, Yi‐Long Wu, Keith M. Kerr, (unknown), D. Ross Camidge, Ravi Gupta, (unknown), Tian Dai, Hossein Borghaei	3
5	The Impact of Co-Alterations on Outcomes after Local Therapy for Patients with KRAS-Mutant Lung Adenocarcinoma Brain Metastases 2023 ·International Journal of Radiation OncologyBiologyPhysics ·(unknown), Bruno Gaëta, Henry Walch, (unknown), Lukáš Kratochvíl, (unknown), Yoshiya Yamada, Changyuan Yu, (unknown), Daniel R. Gomez, Brandon S. Imber, James M. Isbell, B.T. Li, Yonina R. Murciano‐Goroff, Kathryn C. Arbour, N. Schultz, Emily S. Lebow, (unknown)	2
6	MA06.05 CodeBreaK 101: Safety and Efficacy of Sotorasib with Carboplatin and Pemetrexed in KRAS G12C-Mutated Advanced NSCLC 2023 ·Journal of Thoracic Oncology ·Jeffrey Clarke, Enriqueta Felip, B.T. Li, J.C. Ruffinelli, Pilar Garrido, Jon Zugazagoitia, Sarah B. Goldberg, Suresh S. Ramalingam, Iván Victoria, Sonam Puri, David R. Gandara, (unknown), Sally Edmonds, Kerry Palmer, Wendy Snyder, Ramaswamy Govindan, Igor I. Rybkin	12
7	1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non–small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02 2023 ·Annals of Oncology ·B.T. Li, David Planchard, Kōichi Goto, Egbert F. Smit, (unknown), Yasushi Goto, Kiichiro Ninomiya, Toshio Kubo, M. Pérol, Enriqueta Felip, (unknown), Kazuhiko Nakagawa, Junichi Shimizu, Misako Nagasaka, Kaline Pereira, Ayumi Taguchi, Ahmed Ali, Maha Karnoub, (unknown), Pasi A. Jänne	22
8	657MO Recommended phase II dose (RP2D) selection and pharmacodynamic (PD) data of the first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients (pts) with advanced HER2-expressing solid tumors 2023 ·Annals of Oncology ·B.T. Li, Kyung-Woo Lee, Mark D. Pegram, Manish Sharma, Jun Ho Lee, Alexander I. Spira, (unknown), Kathleen N. Moore, Drew Rasco, Glenn J. Hanna, Benjamin A. Weinberg, Tongtong Yu, Marta M. Alonso, Jason Ptacek, Ming Yin, C. Tapia, Lu Xu, Edith A. Perez, Ecaterina E. Dumbrava	3
9	151P Baseline circulating tumor DNA (ctDNA) biomarker analysis of patients with human epidermal growth factor receptor 2 (HER2)-overexpressing metastatic non–small cell lung cancer (NSCLC) treated with trastuzumab deruxtecan (T-DXd) 2023 ·Annals of Oncology ·(unknown), Enriqueta Felip, (unknown), Misako Nagasaka, Kazuhiko Nakagawa, Luis Paz‐Ares, (unknown), B.T. Li, David Planchard, (unknown), Yasushi Goto, Haruyasu Murakami, Kaline Pereira, Ayumi Taguchi, Mikihiko Kogo, Yusuke Kuwahara, (unknown), (unknown), Zenta Tsuchihashi, Pasi A. Jänne	1
10	MA06.08 Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC 2023 ·Journal of Thoracic Oncology ·(unknown), Justin Jee, Robert B. Keller, Alexa B. Schrock, Alexander Drilon, Geoffrey R. Oxnard, B.T. Li	0
11	1361TiP Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02) 2021 ·Annals of Oncology ·Egbert F. Smit, B.T. Li, Julien Mazières, David Planchard, Kazuhiko Nakagawa, Kōichi Goto, Luis Paz‐Ares, Silvia Novello, (unknown), M-J. Ahn, (unknown), Kenneth J. O’Byrne, Mehreteab Aregay, Ryota Shiga, Kapil Saxena, Gudrun Meinhardt, Pasi A. Jänne	1
12	164P Preliminary results from a phase I/II study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors 2021 ·Annals of Oncology ·Monica Sharma, Richard D. Carvajal, Glenn J. Hanna, Yoon‐Koo Kang, (unknown), (unknown), B.T. Li, Kathleen N. Moore, Mark D. Pegram, Drew Rasco, Alexander I. Spira, Dee Dee Wang, Benjamin A. Weinberg, Marta M. Alonso, (unknown), Amreen Husain, Marcin Kowanetz, EA Perez, (unknown)	6
13	LBA45 Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC) 2021 ·Annals of Oncology ·B.T. Li, Egbert F. Smit, Yasushi Goto, Kazuhiko Nakagawa, Hibiki Udagawa, Julien Mazières, Misako Nagasaka, Lyudmila Bazhenova, Andreas Saltos, Enriqueta Felip, (unknown), M. Pérol, Luis Paz‐Ares, Kapil Saxena, Ryota Shiga, Yun Cheng, Suddhasatta Acharyya, Javad Shahidi, David Planchard, Pasi A. Jänne	3
14	MO01.31 Durability of Clinical Benefit and Biomarkers in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) Treated with Sotorasib, a KRAS(G12C) Inhibitor 2021 ·Journal of Thoracic Oncology ·David S. Hong, Yung‐Jue Bang, Fabrice Barlési, Greg Andrew Durm, Gerald S. Falchook, Ramaswamy Govindan, Grace K. Dy, K. Park, John H. Strickler, Timothy F. Burns, (unknown), Agnes Ang, J. Russell Lipford, Gataree Ngarmchamnanrith, Abraham Anderson, B.T. Li	0
15	1257O Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) 2020 ·Annals of Oncology ·David S. Hong, Y-J. Bang, Fabrice Barlési, Greg Andrew Durm, Gerald S. Falchook, Ramaswamy Govindan, Grace K. Dy, K. Park, John H. Strickler, Timothy F. Burns, (unknown), Agnes Ang, J. Russell Lipford, Gataree Ngarmchamnanrith, Abraham Anderson, B.T. Li	6
16	381MO Durability of clinical benefit and biomarkers in patients (pts) with advanced non-small cell lung cancer (NSCLC) treated with AMG 510 (sotorasib) 2020 ·Annals of Oncology ·David S. Hong, Y-J. Bang, Fabrice Barlési, Greg Andrew Durm, Gerald S. Falchook, (unknown), Grace K. Dy, K. Park, John H. Strickler, Timothy F. Burns, (unknown), Agnes Ang, J. Russell Lipford, Gataree Ngarmchamnanrith, Abraham Anderson, B.T. Li	2
17	1785P Phase Ib expansion study of adavosertib plus olaparib in patients with extensive-stage or relapsed small cell lung cancer 2020 ·Annals of Oncology ·B.T. Li, Erika Hamilton, (unknown), Gerald S. Falchook, Amit M. Oza, (unknown), Sanjeev Kumar, Ganesh Mugundu, Elza de Bruin, David R. Spigel, Siqing Fu	1
18	Circulating Tumor DNA as a Biomarker in Oligometastatic Non-small Cell Lung Cancer 2020 ·International Journal of Radiation OncologyBiologyPhysics ·Emily S. Lebow, Yonina R. Murciano‐Goroff, Pedram Razavi, Jorge S. Reis‐Filho, Jessica Flynn, (unknown), Hai‐Yan Tu, (unknown), Lee P. Lim, (unknown), Alexander Drilon, Greg J. Riely, Charles M. Rudin, David R. Jones, Jonathan T. Yang, Andreas Rimner, Maria E. Arcila, James M. Isbell, B.T. Li, Daniel R. Gomez	5
19	A phase II study of [fam-] trastuzumab deruxtecan (DS-8201a) in HER2-overexpressing or -mutated advanced non-small cell lung cancer 2019 ·Annals of Oncology ·David Planchard, B.T. Li, Haruyasu Murakami, Ryota Shiga, (unknown), (unknown), Pasi A. Jänne	7
20	Phase I study of AMG 510, a novel molecule targeting KRAS G12C mutant solid tumours 2019 ·Annals of Oncology ·Ramaswamy Govindan, Marwan Fakih, Timothy Price, Gerald S. Falchook, Jayesh Desai, (unknown), John H. Strickler, John C. Krauss, B.T. Li, (unknown), Greg Andrew Durm, Jude Ngang, Haby Henary, Gataree Ngarmchamnanrith, Erik Rasmussen, (unknown), David S. Hong	30

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact